TET2 and myelodysplastic syndrome: TET2 mutations are common in MDS, found in 11%–33% of cases (7), and are linked to reduced survival post allogeneic HSCT (7). These mutations, mostly loss-of-function, hypermethylate genomic DNA in myeloid cells (22).